Subscribe To

Price Alert Latest News Economic Calendar News

SRRA / Sierra Oncology: Plenty Of Room To Trade Higher After Latest Myelofibrosis Data

Positive results achieved in Phase 3 MOMENTUM study using momelotinib monotherapy for the treatment of myelofibrosis patients who are symptomatic and anemic. Momelotinib has a competitive advantage in that it's not a myelosuppressive agent, this means it provides superior efficacy and quality of life compared to currently approved therapies. Read More

Demo Live Account See Partner Details

Content Topics

Sainsbury

Plc

Sbry

Sierra

Oncology

Plenty

Higher

Latest

Myelofibrosis

Stock

SRRA

Posted: Jan 26 2022, 17:11

Author Name: Seeking Alpha

SRRA News

By Invezz
April 13, 2022

Late-Stage Biopharmaceutical Sierra Oncology announces acquisition by GSK

Sierra Oncology (NASDAQ: SRRA) shares traded significantly higher after announcing the acquisition by GlaxoSmithKline PLC (LON: GSK) for $55 a share i

By InvestorPlace
April 13, 2022

Why Is Sierra Oncology (SRRA) Stock Up Today?

Late-phase cancer treatment company Sierra Oncology is up big today after being acquired by GlaxoSmithKline. SRRA stock is soaring.

By Benzinga
April 13, 2022

Sierra Oncology Stock Is Soaring: Here's Why

Sierra Oncology Inc (NASDAQ: SRRA) shares are trading significantly higher Wednesday after the company announced it will be acquired by GlaxoSmithKlin

By Barrons
April 13, 2022

Sierra Oncology Soars After Takeover by Glaxo

The deal comes ahead of GlaxoSmithKline's planned spinoff of its consumer health division in July.

By Benzinga
April 13, 2022

GlaxoSmithKline Scoops Up Rare Cancer-Focused Sierra Oncology In $1.9B Cash Deal

GlaxoSmithKline plc (NYSE: GSK) has agreed to acquire Sierra Oncology Inc (NASDAQ: SRRA) for $55 per share in cash, representing an approximate tot

By Pulse2
April 13, 2022

Why GlaxoSmithKline (GSK) Is Buying Sierra Oncology (SRRA) For $1.9 Billion

GlaxoSmithKline plc (NYSE: GSK) announced it is buying Sierra Oncology, Inc (Nasdaq: SRRA) for $1.9 billion (£1.5 billion). These are the details.

By Market Watch
April 13, 2022

GlaxoSmithKline to buy Sierra Oncology for $1.9 billion

Pharmaceutical giant GlaxoSmithKline PLC said Wednesday that it is buying biopharmaceutical company Sierra Oncology Inc. for $1.9 billion, and backed

By Reuters
April 13, 2022

GSK to buy Sierra Oncology for $1.9 billion

Britain's GlaxoSmithKline has agreed to buy California-based biopharmaceutical company Sierra Oncology in a deal valued at $1.9 billion, the companies

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.